Markers and Methods for Assessing and Treating Ulcerative Colitis and Related Disorders Using a 20 Gene Panel

• US 20100069256A1
• Filed: 08/31/2009
• Published: 03/18/2010
• Est. Priority Date: 08/29/2008
• Status: Abandoned Application

• Current Assignee: Frederic Baribaud, Xilin Katherine Li
• Original Assignee: Frederic Baribaud, Xilin Katherine Li
• Inventors: Li, Xilin Katherine, Baribaud, Frederic
• Application Number:
  US12/550,703
• Publication Number:
  US 20100069256A1
• Time in Patent Office: Days
• US Class Current: 506/9
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/106 Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: G01N 2800/06 Gastro-intestinal diseases
• CPC Class Codes: G01N 2800/065 Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
• CPC Class Codes: G01N 2800/52 Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
• CPC Class Codes: G01N 33/68 involving proteins, peptides or amino acids involving lipoproteins G01N33/92

Abstract

A method for assessment of the suitability of a target therapy for a gastrointestinal-related disorder, such as ulcerative colitis, in a subject evaluates the presence, absence, and/or magnitude of expression of one or more genes in a 20- or 5-member gene panel in a sample. The method enables identification of the effectiveness of target therapies prior to starting a patient on such therapies.

Claims

1. A method for predicting the suitability of treatment with a target therapy for a gastrointestinal-related disorder in a subject, comprising:

a) preparing a sample of nucleic acids from a specimen obtained from the subject;

b) contacting the sample with a panel of nucleic acid segments consisting of at least a portion of 2 members from the group consisting of the nucleotide sequences corresponding to SEQ ID NOS;

1-20 to detect levels of the panel segments;

c) evaluating the sample against a reference standard to determine the magnitude of change in the amounts of at least 2 members present in the sample; and

d) correlating the magnitude of change with the suitability of treatment with the target therapy for the gastrointestinal-related disorder.

2. The method of claim 1, wherein the subject is a patient having a gastrointestinal-related disorder and the target therapy is an anti-TNFα

antibody.

3. The method of claim 2, wherein the anti-TNFα

antibody is infliximab

4. The method of claim 2, wherein the gastrointestinal-related disorder is ulcerative colitis.

5. The method of claim 4, wherein the reference standard is from a colon biopsy from an untreated ulcerative colitis patient, a responder to the target therapy, or a non-responder to the target therapy.

6. The method of claim 1, wherein the collection is an array of nucleic acid segments.

7. The method of claim 1, wherein the evaluating step comprises evaluating the sample against a reference standard to determine the magnitude of change in the amounts of at least 5 members from the group consisting of the nucleotide sequences corresponding to SEQ ID NOS:

1-20.

8. The method of claim 1, wherein the evaluating step comprises evaluating the sample against a reference standard to determine the magnitude of change in the amounts of at least 10 members from the group consisting of the nucleotide sequences corresponding to SEQ ID NOS:

1-20.

9. The method of claim 1, wherein the evaluating step comprises evaluating the sample against a reference standard to determine the magnitude of change in the amounts of at least 15 members from the group consisting of the nucleotide sequences corresponding to SEQ ID NOS:

1-20.

10. The method of claim 1, wherein the evaluating step comprises evaluating the sample against a reference standard to determine the magnitude of change in the amounts of all members from the group consisting of the nucleotide sequences corresponding to SEQ ID NOS:

1-20.

11. The method of claim 1, wherein the evaluating step comprises evaluating the sample against a reference standard and determining whether the average intensity value for each of the members of the panel is equal to or above X or below Y.

12. The method of claim 11, wherein the average intensity value for each of the members of the panel being equal to or above X indicates the subject will be a responder to the target therapy and the average intensity value for each of the members of the panel being below Y indicates the subject will be a non-responder.

13. The method of claim 12, further comprising after the correlating step, treating in the subject with the target therapy based on the average intensity value for each of the members of the panel being equal to or above X.

14. The method of claim 12, further comprising after the correlating step, refraining from treating the subject with the target therapy based on the average intensity value for each of the members of the panel being less than Y.

15. The method of claim 2, wherein the sample is from a source selected from the group consisting of a patient providing the sample prior to administration of a therapy, a placebo treated patient having a gastrointestinal-related disorder, and a sample from a biobank.

16. The method of claim 1, wherein the sample comprises a colon biopsy sample.

17. The method of claim 1, wherein the sample comprises peripheral blood cells.

18. A method for predicting the suitability of treatment with a target therapy for a gastrointestinal-related disorder in a subject, comprising:

e) preparing a sample of nucleic acids from a specimen obtained from the subject;

f) contacting the sample with a panel of nucleic acid segments consisting of at least one member from the group consisting of the nucleotide sequences corresponding to SEQ ID NOS;

3, 5, 9, 10, and 14 to detect the levels of the panel segments;

g) evaluating the sample against a reference standard to determine the magnitude of change in the amount of the at least one member present in the sample; and

h) correlating the magnitude of change with the suitability of treatment of the target therapy for the gastrointestinal-related disorder.

19. The method of claim 18, wherein the subject is a patient having a gastrointestinal-related disorder and the target therapy is an anti-TNFα

antibody.

20. The method of claim 19, wherein the anti-TNFα

antibody is infliximab.

21. The method of claim 19, wherein the gastrointestinal-related disorder is ulcerative colitis.

22. The method of claim 19, wherein the reference standard is from a colon biopsy from an untreated ulcerative colitis patient.

23. The method of claim 18, wherein the collection is an array of nucleic acid segments.

24. The method of claim 18, wherein the evaluating step comprises evaluating the sample against a reference standard to determine the magnitude of change in the amounts of at least 2 members from the group consisting of the nucleotide sequences corresponding to SEQ ID NOS:

3, 5, 9, 10, and 14.

25. The method of claim 18, wherein the evaluating step comprises evaluating the sample against a reference standard to determine the magnitude of change in the amounts of at least 3 members from the group consisting of SEQ ID NOS:

3, 5, 9, 10, and 14.

26. The method of claim 18, wherein the evaluating step comprises evaluating the sample against a reference standard to determine the magnitude of change in the amounts of at least 4 members from the group consisting of the nucleotide sequences corresponding to SEQ ID NOS:

3, 5, 9, 10, and 14.

27. The method of claim 18, wherein the evaluating step comprises evaluating the sample against a reference standard to determine the magnitude of change in the amounts of all members of the nucleotide sequences corresponding to SEQ ID NOS:

3, 5, 9, 10, and 14.

28. The method of claim 24, wherein the evaluating step comprises evaluating the sample against a reference standard and determining whether the average intensity value of each of the members of the panel is equal to or above X or below Y.

29. The method of claim 25, wherein the evaluating step comprises evaluating the sample against a reference standard and determining whether the average intensity value of each of the members of the panel is equal to or above X or below Y.

30. The method of claim 26, wherein the evaluating step comprises evaluating the sample against a reference standard and determining whether the average intensity value of each of the members of the panel is equal to or above X or below Y.

31. The method of claim 27, wherein the evaluating step comprises evaluating the sample against a reference standard and determining whether the average intensity value of each of the members of the panel is equal to or above X or below Y.

32. The method of claim 28, further comprising after the correlating step, treating the subject with the target therapy based on the average intensity value for each of the members of the panel being equal to or above X.

33. The method of claim 28, further comprising after the correlating step, refraining from treating the subject with the target therapy based on the average intensity value for each of the members of the panel being less than Y.

34. The method of claim 18, wherein the sample is from a source selected from the group consisting of a patient providing the sample prior to administration of a therapy, a placebo treated patient having a gastrointestinal-related disorder, and a sample from a biobank.

35. The method of claim 18, wherein the sample comprises a colon biopsy sample.

36. The method of claim 18, wherein the sample comprises peripheral blood cells.

37. An array-based testing method for predicting the suitability of treatment with a target therapy for a gastrointestinal-related disorder in a patient, comprising:

a) preparing a mixture of nucleic acids from a specimen obtained from the patient;

b) labeling said specimen nucleic acids with a detectable marker to form a sample;

c) contacting the sample with an array comprising a plurality of nucleic acid segments, wherein each nucleic acid segment is immobilized to a discrete and known address on a substrate surface of the array, wherein at least two members of a gastrointestinal-related gene panel consisting of the nucleotide sequences corresponding to SEQ ID NOS;

1-20 are identified as features of the array by address, and wherein said array further comprises at least one calibration nucleic acid at a known address on the substrate;

d) determining the degree of binding of the specimen nucleic acids to the nucleic acid segments; and

e) comparing the degree of binding to a reference standard to enable an assessment of the suitability of treatment.

38. The method of claim 37, wherein the comparing step comprises evaluating the sample against a reference standard to determine the magnitude of change in the amounts of at least two of the members of the nucleotide sequences corresponding to SEQ ID NOS:

1-20.

39. The method of claim 38, wherein the evaluating step comprises evaluating the sample against a reference standard and determining whether the average intensity value for each of the members of the gastrointestinal-related gene panel is equal to or above X or below Y.

40. The method of claim 37, wherein the gastrointestinal-related disorder is ulcerative colitis and the gastrointestinal-related gene panel is an ulcerative colitis-related gene panel.

41. The method of claim 37, wherein the target therapy is an anti-TNFα

antibody.

42. The method of claim 37, wherein the specimen is from a colon biopsy of a patient selected from the group consisting of patients suspected of having ulcerative colitis and patients diagnosed with ulcerative colitis not undergoing treatment.

43. The method of claim 37, wherein the specimen is from a source selected from the group consisting of a patient providing the specimen prior to administration of a therapy, a patient having a similar disease or condition treated with a placebo, and a sample from a biobank.

44. The method of claim 37, wherein the specimen comprises a colon biopsy sample.

45. The method of claim 37, wherein the specimen comprises peripheral blood cells.

46. The method of claim 37, wherein the comparing the degree of binding step further comprises a stringent test of the similarity of feature intensity changes of the array of the ulcerative colitis-related gene panel.

47. A reagent for testing the suitability of a target therapy for a gastrointestinal-related disorder in a cell or subject, comprising at least one member selected from the group consisting of an oligonucleotide comprising at least 15 nucleotides comprising or complementary to a nucleotide sequence of one of the nucleotide sequences corresponding to SEQ ID NOS:

1-20, a polypeptide encoded by at least a portion of one of the nucleotide sequences corresponding to SEQ ID NOS;

1-20, and a ligand for the polypeptide encoded by at least a portion of one of the nucleotide sequences corresponding to SEQ ID NOS;

1-20.

48. The reagent of claim 47, wherein the gastrointestinal-related disorder is ulcerative colitis and the target therapy is an anti-TNFα

antibody.

49. The reagent of claim 48, wherein the anti-TNFα

antibody is infliximab.

50. A method of testing the suitability of a target therapy for a gastrointestinal-related disorder in a patient sample comprising contacting the patient sample with the reagent of claim 47 and comparing the levels of at least a portion of one of the genes or proteins of the nucleotide sequences corresponding to SEQ ID NOS:

1-20 to a reference standard.

51. The method of claim 50, wherein the testing is done by RT-PCR.

52. The method of claim 50, wherein the testing is done by ELISA.

53. The method of claim 50, wherein the target therapy is an anti-TNFα

antibody.

54. The method of claim 53, wherein the antibody is infliximab.

55. The method of claim 50, further comprising evaluating the sample against a reference standard and determining whether the average intensity value for each of the members of the gastrointestinal-related gene panel is equal to or above X or below Y.

59. A method of testing the effectiveness of a therapy for ulcerative colitis, comprising:

a) contacting a sample from a patient being treated for ulcerative colitis with at least two members of the reagent of claim 47;

b) measuring levels of the at least two members; and

c) correlating the levels of the at least two members with the effectiveness of the therapy.

60. The method of claim 59, wherein the therapy comprises an antagonist of TNFα

.

61. The method of claim 60, wherein the antagonist is an antibody to TNFα

.

62. The method of claim 61, wherein the antibody is infliximab.

56. A kit for prognostic or diagnostic use, comprising an oligonucleotide comprising at least 15 nucleotides comprising or complementary to a polynucleotide comprising the nucleotide sequence of a marker gene or the complementary strand thereof and cells expressing the marker gene, wherein the marker gene is selected from the group consisting of the nucleotide sequences corresponding to SEQ ID NOS:

1-20.

57. The kit of claim 56, wherein the kit is adapted for screening the suitability of a therapeutic agent for UC.

58. A kit for screening the suitability of a therapeutic agent for UC, the kit comprising an antibody which recognizes a peptide comprising an amino acid sequence encoded by a marker gene and cells expressing the marker gene, wherein the marker gene is selected from the group consisting of the nucleotide sequences corresponding to SEQ ID NOS:

1-20.

63. A method for treating a subject having a gastrointestinal-related disorder with a target therapy, comprising:

a) preparing a sample of nucleic acids from a specimen obtained from the subject;

b) contacting the sample with a panel of nucleic acid segments consisting of at least a portion of 2 members from the group consisting of the nucleotide sequences corresponding to SEQ ID NOS;

1-20 to detect levels of the panel segments;

c) evaluating the sample against a reference standard to determine the magnitude of change in the amounts of at least 2 members present in the sample;

d) correlating the magnitude of change with the suitability of treatment with the target therapy for the gastrointestinal-related disorder; and

e) treating the subject with the target therapy.

64. Any invention described herein.